RhoA Modulates Functional and Physical Interaction Between ROCK1 and Erk1/2 in Selenite-induced Apoptosis of Leukaemia Cells

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2013 Jul 6

PMID 23828571

Citations 27

Authors

F Li

Q Jiang

K J Shi

H Luo

Y Yang

C M Xu

Affiliations

Soon will be listed here.

Abstract

RhoA GTPase dysregulation is frequently reported in various tumours and haematologic malignancies. RhoA, regulating Rho-associated coiled-coil-forming kinase 1 (ROCK1), modulates multiple cell functions, including malignant transformation, metastasis and cell death. Therefore, RhoA/ROCK1 could be an ideal candidate target in cancer treatment. However, the roles of RhoA/ROCK1 axis in apoptosis of leukaemia cells remain elusive. In this study, we explored the effects of RhoA/ROCK1 cascade on selenite-induced apoptosis of leukaemia cells and the underlying mechanism. We found selenite deactivated RhoA/ROCK1 and decreased the association between RhoA and ROCK1 in leukaemia NB4 and Jurkat cells. The inhibited RhoA/ROCK1 signalling enhanced the phosphorylation of Erk1/2 in a Mek1/2-independent manner. Erk1/2 promoted apoptosis of leukaemia cells after it was activated. Intriguingly, it was shown that both RhoA and ROCK1 were present in the multimolecular complex containing Erk1/2. GST pull-down analysis showed ROCK1 had a direct interaction with GST-Erk2. In addition, selenite-induced apoptosis in an NB4 xenograft model was also found to be associated with the RhoA/ROCK1/Erk1/2 pathway. Our data demonstrate that the RhoA/ROCK1 signalling pathway has important roles in the determination of cell fates and the modulation of Erk1/2 activity at the Mek-Erk interplay level.

Citing Articles

GPCR-Gα13 Involvement in Mitochondrial Function, Oxidative Stress, and Prostate Cancer.

Wu D, Casey P Int J Mol Sci. 2024; 25(13).

PMID: 39000269 PMC: 11241654. DOI: 10.3390/ijms25137162.

Characterization of Anticancer Effects of the Analogs of DJ4, a Novel Selective Inhibitor of ROCK and MRCK Kinases.

Kale V, Hengst J, Sharma A, Golla U, Dovat S, Amin S Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37630974 PMC: 10458458. DOI: 10.3390/ph16081060.

Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review.

Corbic M, Sretenovic J, Zivkovic V, Jakovljevic V, Nikolic Turnic T Iran J Public Health. 2023; 52(5):870-879.

PMID: 37484720 PMC: 10362213. DOI: 10.18502/ijph.v52i5.12704.

Apigenin Attenuates Hippocampal Microglial Activation and Restores Cognitive Function in Methotrexate-Treated Rats: Targeting the miR-15a/ROCK-1/ERK1/2 Pathway.

Taha M, Eldemerdash O, Elshaffei I, Yousef E, Soliman A, Senousy M Mol Neurobiol. 2023; 60(7):3770-3787.

PMID: 36943623 PMC: 10224822. DOI: 10.1007/s12035-023-03299-7.

RHOA Therapeutic Targeting in Hematological Cancers.

Santos J, Profitos-Peleja N, Sanchez-Vinces S, Roue G Cells. 2023; 12(3).

PMID: 36766776 PMC: 9914237. DOI: 10.3390/cells12030433.

References

Heasman S, Ridley A . Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 2008; 9(9):690-701. DOI: 10.1038/nrm2476. View

Ung C, Li H, Ma X, Jia J, Li B, Low B . Simulation of the regulation of EGFR endocytosis and EGFR-ERK signaling by endophilin-mediated RhoA-EGFR crosstalk. FEBS Lett. 2008; 582(15):2283-90. DOI: 10.1016/j.febslet.2008.05.026. View

Molli P, Pradhan M, Advani S, Naik N . RhoA: a therapeutic target for chronic myeloid leukemia. Mol Cancer. 2012; 11:16. PMC: 3353160. DOI: 10.1186/1476-4598-11-16. View

Nobes C, Hall A . Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol. 1999; 144(6):1235-44. PMC: 2150589. DOI: 10.1083/jcb.144.6.1235. View

Jacobs M, Hayakawa K, Swenson L, Bellon S, Fleming M, Taslimi P . The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem. 2005; 281(1):260-8. DOI: 10.1074/jbc.M508847200. View

Han B, Wei W, Hua F, Cao T, Dong H, Yang T . Requirement for ERK activity in sodium selenite-induced apoptosis of acute promyelocytic leukemia-derived NB4 cells. J Biochem Mol Biol. 2007; 40(2):196-204. DOI: 10.5483/bmbrep.2007.40.2.196. View

Gallagher E, Gutowski S, Sternweis P, Cobb M . RhoA binds to the amino terminus of MEKK1 and regulates its kinase activity. J Biol Chem. 2003; 279(3):1872-7. DOI: 10.1074/jbc.M309525200. View

Burthem J, Rees-Unwin K, Mottram R, Adams J, Lucas G, Spooncer E . The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells. Leukemia. 2007; 21(8):1708-14. DOI: 10.1038/sj.leu.2404762. View

Tybulewicz V, Henderson R . Rho family GTPases and their regulators in lymphocytes. Nat Rev Immunol. 2009; 9(9):630-44. PMC: 4898593. DOI: 10.1038/nri2606. View

10.

Shin S, Dimitri C, Yoon S, Dowdle W, Blenis J . ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell. 2010; 38(1):114-27. PMC: 2854677. DOI: 10.1016/j.molcel.2010.02.020. View

11.

Jiang Q, Wang Y, Li T, Shi K, Li Z, Ma Y . Heat shock protein 90-mediated inactivation of nuclear factor-κB switches autophagy to apoptosis through becn1 transcriptional inhibition in selenite-induced NB4 cells. Mol Biol Cell. 2011; 22(8):1167-80. PMC: 3078072. DOI: 10.1091/mbc.E10-10-0860. View

12.

von Kriegsheim A, Baiocchi D, Birtwistle M, Sumpton D, Bienvenut W, Morrice N . Cell fate decisions are specified by the dynamic ERK interactome. Nat Cell Biol. 2009; 11(12):1458-64. PMC: 3839079. DOI: 10.1038/ncb1994. View

13.

Shi Y, Li H, Zhang X, Fu Y, Huang Y, Lui P . Continuous cyclic mechanical tension inhibited Runx2 expression in mesenchymal stem cells through RhoA-ERK1/2 pathway. J Cell Physiol. 2011; 226(8):2159-69. DOI: 10.1002/jcp.22551. View

14.

Fukuda M, Gotoh I, Gotoh Y, Nishida E . Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal. J Biol Chem. 1996; 271(33):20024-8. DOI: 10.1074/jbc.271.33.20024. View

15.

Selleri C, Maciejewski J, Montuori N, Ricci P, Visconte V, Serio B . Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells. Blood. 2003; 102(4):1490-8. DOI: 10.1182/blood-2003-01-0178. View

16.

Hebert M, Potin S, Sebbagh M, Bertoglio J, Breard J, Hamelin J . Rho-ROCK-dependent ezrin-radixin-moesin phosphorylation regulates Fas-mediated apoptosis in Jurkat cells. J Immunol. 2008; 181(9):5963-73. DOI: 10.4049/jimmunol.181.9.5963. View

17.

Duhamel S, Hebert J, Gaboury L, Bouchard A, Simon R, Sauter G . Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation. Cancer Res. 2012; 72(3):626-35. DOI: 10.1158/0008-5472.CAN-11-2126. View

18.

Li Z, Shi K, Guan L, Cao T, Jiang Q, Yang Y . ROS leads to MnSOD upregulation through ERK2 translocation and p53 activation in selenite-induced apoptosis of NB4 cells. FEBS Lett. 2010; 584(11):2291-7. DOI: 10.1016/j.febslet.2010.03.040. View

19.

Mulloy J, Cancelas J, Filippi M, Kalfa T, Guo F, Zheng Y . Rho GTPases in hematopoiesis and hemopathies. Blood. 2009; 115(5):936-47. PMC: 2817638. DOI: 10.1182/blood-2009-09-198127. View

20.

Ferrara F . Acute promyelocytic leukemia: what are the treatment options?. Expert Opin Pharmacother. 2010; 11(4):587-96. DOI: 10.1517/14656560903505115. View